charles hoopes md university of kentucky

46
Charles Hoopes MD University of Kentucky Veno-arterial ECLS for cardiogenic shock STS Symposium: Mechanical Circulatory Support for Advanced Cardiopulmonary Disease September 2013 Chicago I have no financial interests in any of the technologies discussed and nothing to disclose

Upload: aine

Post on 31-Jan-2016

46 views

Category:

Documents


0 download

DESCRIPTION

Veno-arterial ECLS for cardiogenic shock. STS Symposium: Mechanical Circulatory Support for Advanced Cardiopulmonary Disease September 2013 Chicago I have no financial interests in any of the technologies discussed and nothing to disclose. Charles Hoopes MD University of Kentucky. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Charles Hoopes MD University of Kentucky

Charles Hoopes MDUniversity of Kentucky

Veno-arterial ECLS for cardiogenic shock

STS Symposium: Mechanical Circulatory Support for Advanced Cardiopulmonary Disease September 2013 Chicago

I have no financial interests in any of the technologies discussed and nothing to disclose

Page 2: Charles Hoopes MD University of Kentucky

Questions & learning objectives…ECLS & cardiogenic shock

Is “salvage” ECLS in the patient with cardiopulmonary collapse an evidence based approach … the clinical rationale for and clinical limitations of ECMO

What are the physiological goals of ECLS in cardiogenic shock … what are the biological and clinical markers of success ?

How does “emergent” ECLS in the patient with cardiogenic shock change the options and the risk profile of subsequent durable LVAD implantation and transplant ?

Page 3: Charles Hoopes MD University of Kentucky

“Our interventionists had a case recently where patient had a LAD PCI then was brought back a couple of days later for a RCA mid lesion.  She arrested on insertion of the catheter in the aortic root -- never did a manipulation -- and after initial unsuccessful resuscitation, placed an impella and kept it up.  They injected her L and it was open and, while still arrested opened the mid RCA.  They called us after about 45 min of arrest when she was still in asystole.  We then had ECMO there but  by then it was an hour of arrest with no rhythm and felt ECMO would be futile.  Do you have or know of any experience that would justify a trial of ECMO in this situation.  I could understand if it was a bridge to recovery with severe shock, but with a rhythm -- or if there was a L main or other proximal lesion to open.”

veno-arterial ECMO/ECLS ?

Page 4: Charles Hoopes MD University of Kentucky

41 yo male Vfib arrest (in house) … total occlusionLAD. Acute thrombosis of RCA during LAD PCI … ventricular arrhythmias with cardioversions x 16.

IABP and Impella 2.5 … transferred to ICU with patent LAD, recurrent thrombosis of RCA (100% mid), inotropes. Clotting diathesis … ?

24 hours post cath … CI 1.6, Cr 5.5, AST > 5000, lactate > 6 …Q’s in II, III, aVF … trops > 50. Adequate gas exchange …

Return to cath lab … patent LAD, 100% mid RCA … Vfib

veno-arterial ECMO/ECLS ?

Page 5: Charles Hoopes MD University of Kentucky

“Defibrillation was attempted again but remained unsuccessful. CPR continued. We suspected that the patient’s heart was too distendedto permit termination of ventricular fibrillation … a decision was made to consult cardiac surgery about the initiation of extracorporeal membrane oxygenation (ECMO) for full hemodynamic support and to decompress the heart and facilitate termination of ventricular fibrillation.”

n engl j med 369;11 nejm.org september 12, 2013

Page 6: Charles Hoopes MD University of Kentucky

Pubmed search: “ECMO and cardiogenic shock” … 403 citations (60% w/in the past 60 months)

… the large randomized IABP-Shock II Trial did not show a significant reduction in 30-day mortality in cardiogenic shock with IABP insertion.

… both the Impella pump and the Tandem Heart did not reduce 30-day mortality when compared with IABP in small randomized controlled trials

… no randomized study data available for ECMO/ECLS use in cardiogenic shock

Page 7: Charles Hoopes MD University of Kentucky

Trends in hospital case fatality rates in patients with acute myocardial infarct according to the presence of cardiogenic shock.

Trends in the incidence rates of cardiogenic shock in patients with acute myocardial infarcts.

Goldberg et al. Thirty-year trends (1975 to 2005) in the magnitude of,management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction Circulation 2009;119:1211

40%

1 in 20

Page 8: Charles Hoopes MD University of Kentucky

Is ECLS the answer ?

30% survival to discharge !

Page 9: Charles Hoopes MD University of Kentucky

ELSO Registry Jan 2010

Page 10: Charles Hoopes MD University of Kentucky

Among 98 patients …

cardiogenic shock (34), ventricular fibrillation or pulseless ventricular tachycardia (23), or asystole /pulseless electrical activity (41)

96% underwent emergency revascularization (2 received CABG)with successful angioplasty achieved in 71% (TIMI 3 flow)

55% were weaned from ECLS …

ECLS-related complications occurred in 36%... cannulation site bleeding

All-cause in-hospital mortality rate was 67.3%,and the survival rate to hospital discharge was 32.7%

Page 11: Charles Hoopes MD University of Kentucky

“ …disappointing results for the sole use of ECLS … aggressive initiation of ECLS could improve survival rates to 70% to 80% … the reason for cardiac surgeons to understand its lessons:

Prolonged cardiogenic shock carries a high mortality without a plan for definitive additional therapy

Revascularization in the setting of cardiogenicshock provides little or no additional benefit andin the short term may be detrimental by delaying definitive support

ECLS is an effective method of early resuscitation of the moribund patients in shock … its effectiveness depends on end organ ischemic time, early ventricular recovery, or use of more definitive devices for long-term support”

Invited CommentaryGeorge L Hicks, MDUniversity of Rochester Medical Center

Page 12: Charles Hoopes MD University of Kentucky

“ECMO in advanced refractory AMI-CS is associated with acceptable outcomes in a well-selected population.

ECMO in patients with an acute decompensation of a chronic cardiomyopathy should be carefully considered to avoid futile support.”

Kaplan-Meier survival curve of all patients supported on ECMO for cardiogenic shock (subsequent management strategies included revascularization, VAD, or heart transplantation)

Bermudez et al (2011) ECMO for advanced refractory shock in acute and chronic cardiomyopathy. AnnThorac Surg 92:2125

ischemic 50% at 6 mos

non-ischemic 20%

Page 13: Charles Hoopes MD University of Kentucky

Cannulation and initiation of flow … vascular access, gas exchange , and flow

Do what you need to get what you want …

perfusion w/o ischemia

adequate hemodynamics

“viable patient”

Engineering should inform the discussionaround patient care …

“Thought algorithms” vs “protocols”

ECMO: simple operation, complex procedure

Page 14: Charles Hoopes MD University of Kentucky

ECMO resuscitates the moribound … it cannot reanimate the dead … question of patient viability or myocardial recovery

ECMO remains a non-durable technology …

ECLS is a simple procedure, extracorporeal technologies are a complex management paradigm

ECLS accomplishes nothing (it is non-therapeutic), butfacilitates everything

“Truisms” about ECLS/ECMO …

Page 15: Charles Hoopes MD University of Kentucky

Two types of ECMO/ECLS program … public health perspective … clinical goals define infrastructure (technology and personnel)

Acute stabilization and short term transfer“moratorium of decision” programs (in house … cath lab, ED, OR)duration of support < 72 hrs, limited infrastructure

rapid deployment technology (non-durable technologies)

Integrated programs (ICU and/or transplant)

“recovery” and “bridge to transplant” (referral based)duration of support > 72 hrs, extended infrastructure (MCS)durable technologies (“ambulatory ECMO”)

… institutional culture and hospital structure impact on ECLS program design

Page 16: Charles Hoopes MD University of Kentucky

The 30-day mortality rate in patients with witnessed OHCA undergoing ECLS treatment can be significantly improved if ECLS support is established within the first 30 min after admission …rdECMO

Leick et al (2013) Door-to-implantation time of extracorporeal life support systems predicts mortality in patients with out-of-hospital cardiac arrest. Clin Resarch Cardiol 102:661.

Page 17: Charles Hoopes MD University of Kentucky

Sheu et al (2010) ECMO assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med 38:1810.

Page 18: Charles Hoopes MD University of Kentucky

Basic ECMO… Cannulation...clinical need determines strategy

femoral vein to IJ (traditional VV)femoral vein to femoral artery (traditional VA)femoral vein and RIJ to femoral artery (VVA)RIJ dual lumen and subclavian artery (“walking hybrid”)RA to Ao (central VA)..”ambulatory CPB” (VAD)RA to PA…right heart bypass (VAD)PA to LA…right heart bypass (VAD)RIJ dual lumen cannula (VV Avalon DLC)RIJ dual lumen and femoral artery (VVA “sedate hybrid”)femoral artery to RA (AV) …reverse “pumpless” arterio-venous cannulation (pECLA)

Membrane oxygenator (Quadrox)

Centrifugal blood pump (Centrimag or Rotaflow), roller pump, or “native flow” (cardiac output)

Anticoagulation (heparin ACT “point of care”, TEG)

Personnel (MCS service line or ECMO specialists)

Page 19: Charles Hoopes MD University of Kentucky

Cardiopulmonary collapse (circulatory arrest)

“salvage” ECLS

CPR

Cardiogenic shock (INTERMACs I)

“emergent” ECLS

“moratorium of decision” … end organ injury

“bridge to recovery” … myocardial injury

“bridge to definitive therapy” … non-durable to durable support

(…application and deployment)

Page 20: Charles Hoopes MD University of Kentucky

Cannulation …

Peripheral veno-arterial ECLS

RA/femoral vein…retrograde femoral a. (ECMO)RA…antegrade right subclavian a. (8mm Dacron graft/ECMO)LA/femoral trans-septal …retrograde femoral a.

Central veno-arterial ECLS RA to pulmonary a. (right heart)LA to aorta (VAD)RA to aorta (ECMO)

(…application and deployment)

Page 21: Charles Hoopes MD University of Kentucky

Femoral cannulation for veno-arterial (VA) ECMO …

RA/IVC drainage from CFV access (23/25F)

…venous return limits flow

Arterial inflow (17F) … “downsize”

Distal arterial inflow (6F) … “downsize”

…“open” versus “percutaneous” access ?*no complications *exit strategy

Page 22: Charles Hoopes MD University of Kentucky

Retrograde arterial flow … LVEF and cerebral perfusion, LVEDP !

Distal malperfusion …

The patient … sedate and non-ambulatory

Blood path and directional flow …

VAda ECMO

VenoArterial (distal artery)ECMO

Non physiologic and inherentlyunstable

Efficacy proportional to LVEF

Page 23: Charles Hoopes MD University of Kentucky

Aziz et al (2010) Initial experience with CentriMag extracorporal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock JHLT 29:66

Page 24: Charles Hoopes MD University of Kentucky

Determine blood flow requirements …

Neonate 100 to 150 mL/min/kgPediatric 75 to 120 mL/min/kgAdult 50 to 80 mL/min/kg

Assumptions: “flow is laminar viscous and incompressible …and the flow is through a constant circular cross-section …”

In reality:Flow is rarely laminar …Hct and temp affect viscosity …The cross sectional area is a composite of fixed (cannula) and variable (vessels) components

Page 25: Charles Hoopes MD University of Kentucky

…standardized system to describe the pressure-flow characteristics of a given cannula … if specific flows are needed to support a given patient, an arterial and venous cannula of an adequate M-number can be chosen from a given nomogram that will support flow at acceptable pressures

Page 26: Charles Hoopes MD University of Kentucky

A single number that represents the relationship between cannula size, flow, and pressure drop.

M-number for tubing: 1/4 inch, 1 meter M= 3.13/8 inch, 1 meter M= 2.01/2 inch, 1 meter M= 0.9Assuming non-turbulent blood flow

M-number : resistance

Page 27: Charles Hoopes MD University of Kentucky

18F (6.0mm)20F (6.7mm)22F (7.3mm) 24F (8.0mm)28F (9.3mm)

Cannulation …

55 cm (21.6”)68 cm (26.8”)

16F (5.3mm) 18F (6.0m

20F (6.7mm)22F (7.3mm)

Page 28: Charles Hoopes MD University of Kentucky

Femoral VA ECMO … low EF

non-physiological: retrograde blood path with limited pulmonary blood flow (oxygenator)

decreased LV pre-load … myocardial recovery

increased LVEDP … capillary leakand acute lung injury

gas exchange … membrane oxygenator

cannulation … limb ischemia

This is not cardiopulmonary bypass … thereis no venous reservoir

Page 29: Charles Hoopes MD University of Kentucky

RV

VA ECMO is not CPB … any decrease in pre-load is atthe expense of increasedafterload

Left ventricular stasis …elevated LVEDP with pulmonaryedema and LV thrombus

Vent, apical cannulation, septostomy, anticoagulation, or..“hybrid procedure” … VA ECMOand antegrade technology

Veno-arterial ECLS in cardiogenic shock

Page 30: Charles Hoopes MD University of Kentucky

Acute lung injury after mechanical circulatory support implantation in patients on extracorporeal life support: an unrecognized problem. Boulatea et al (2013) European Journal of Cardio-Thoracic Surgery 44: 544–550

Page 31: Charles Hoopes MD University of Kentucky

Femoral VA ECMO … with myocardial recovery

limited retrograde blood path with significant pulmonary blood flow (oxygenator)

increased LV pre-load … myocardial recovery

decreased LVEDP … no lung injury

gas exchange … mixed …membrane oxygenatorand lungs

cannulation … lower limb ischemia

Page 32: Charles Hoopes MD University of Kentucky

90

80

70

60

50

3.0 5.5Cardiac output (L/min)

Mean a

rteri

al pre

ssure

Cardiac power output > 0.6

Veno-arterial ECLS targeted flow rates …

Management algorithms are complicated by inadequate predictors of myocardial recovery … ECHO and markers of perfusion

CPO = MAP x CO/451

Page 33: Charles Hoopes MD University of Kentucky

RIJ-subclavian VA ECMO

antegrade blood path with significant pulmonary blood flow (oxygenator)

increased LV pre-load … myocardial recovery

decreased LVEDP …

gas exchange … mixed …membrane oxygenatorand lungs

cannulation … upper limb ischemia

RA

8mm Dacron

Page 34: Charles Hoopes MD University of Kentucky

Subclavian Artery Cannulation for Venoarterial Extracorporeal Membrane Oxygenation.Javidfar, Jeffrey; Brodie, Daniel; Costa, Joseph; Miller, Joanna; Jurrado, Julissa; LaVelle, Matthew; Newmark, Alexis; Takayama, Hiroo; Sonett, Joshua; Bacchetta, Matthew

ASAIO Journal. 58(5):494-498, September/October 2012.DOI: 10.1097/MAT.0b013e318268ea15

Page 35: Charles Hoopes MD University of Kentucky

RIJ dual lumen VV-subclavian Arterial ECMO … hybrid ECMO (venoveno-arterial)

antegrade flow … mixed cardiopulmonary disease

“hybrid” VVA, or full VV, or full VA

support technology … not salvage

ambulatoryRA

8mm Dacron

Brodie and Bacchetta (2011) NEJM

Page 36: Charles Hoopes MD University of Kentucky

…percutaneous approach

… trans-septal left ventricular unloading

Page 37: Charles Hoopes MD University of Kentucky

Evolving applications … “virtual VVA ECMO”

cor pulmonale and pulmonary veno-occlussive disease

68 yo scleroderma variant, elevated ANA…supra-systemic PApressures on continuous dobutamine, lasix qtt, high flow O2. Failed vasodilator therapy x 3…non-ambulatory with progressivesyncopal episodes…

To cath lab…combined atrial septostomy and right IJ dual lumenvenovenous ECMO cannulation…bridge to transplant (ECMO day 4)

Page 38: Charles Hoopes MD University of Kentucky

Cannulation …

Peripheral veno-arterial ECLS

RA/femoral vein…retrograde femoral a. (ECMO)RA…antegrade right subclavian a. (8mm Dacron graft/ECMO)LA/femoral trans-septal …retrograde femoral a.

Central veno-arterial ECLS RA to pulmonary a. (right heart)LA to aorta (VAD)RA to aorta (ECMO)

(…application and deployment)

Page 39: Charles Hoopes MD University of Kentucky

Central cannulation …

Page 40: Charles Hoopes MD University of Kentucky

Central cannulation …

PA

LA

Page 41: Charles Hoopes MD University of Kentucky

… integrated MCS ECMO cardiogenic shock …femoral ECMO … to central ECMO …to LVAD and oxyRVAD with RV failure…to long-term Centrimag RVAD support

… bridge to transplant

Page 42: Charles Hoopes MD University of Kentucky

Cannulation and initiation … ten general rules and painful lessons

1. re-think “application” … why am I doing this and what do I hope to accomplish

2. re-think “deployment” … “this” cannulation strategy … “now?”

3. Got heparin ? (0.5 mg/kg) … plan an anticoagulation strategy

4. Crystalloid prime … or colloid prime (FFP)

5. Look at your lines … air, clamps, length, and entry points

6. Come up slowing … establish flow, then increase flow

7. Remember the patient … inotropes and airway (minute ventilation is 15L/min … sweep is 10L ...!!!)

8. Most disasters happen five minutes after the celebration begins .. This is a human endeavor

9. Any surgical bleeding is unacceptable

10. Have an exit strategy

Page 43: Charles Hoopes MD University of Kentucky

… mortality assessment of pre-operative risk factors that might serve as targets for goal-directed interventions meant to improve LVAD candidate survival (age, albumin, renal and hepatic insufficiency,center experience)

“… preserved end-organ function, however preoperatively achieved, might be the most important predictor of successful LVAD outcome.”

Low risk < 1.58Medium risk: 1.58 to 2.48High risk > 2.48

Cowger et al (2013) Predicting Survival in Patients ReceivingContinuous Flow Left Ventricular Assist Devices:The HeartMate II Risk Score. J Am Coll Cardiol. 61:313–21

Page 44: Charles Hoopes MD University of Kentucky

bilirubin

AST

Na

lactate

Can pre-operative ECMO alter the patient risk profile of LVAD implantation …

Or does it simply make the numbers better…with the additional morbidity of a pre-implantprocedure?

Cr

LVAD

ECMO

RVAD

RVAD explant

Page 45: Charles Hoopes MD University of Kentucky

ECLS

LVAD

Creatinine

AST

Bilirubin

The Right Ventricular Failure Risk Score (RVFRS):A pre-operative tool for assessing the risk of rightventricular failure in left ventricular assist device candidates

Vasopressor requirement (4)AST > 80 (2)Bilirubin > 2 (2.5)Cr > 2.3 (3)

Low risk (OR 0.5) RVFRS < 3 (90% six mo survival)High risk (OR 7.6) RVFRS > 5.5 (66% six mo survival)

Pre ECMO RVFRS score … 11.5Post ECMO RVFRS score … 2.5

Can pre-operative ECMO convert a patientat high risk for biventricular support into a“conventional” LVAD recipient?

Matthews at al (2008) JACC 51:2163

Page 46: Charles Hoopes MD University of Kentucky

Deployment of ECMO technologies in the context of medical futility generally results in futile deployment of technology…it is rarely “the device”

ECMO technology generally restores physiology but may not alter survival depending upon the specifics of deployment

ECMO can support patients awaiting good clinical decision making … it is ineffective in supporting bad clinical decisions

ECLS and cardiogenic shock…